153 related articles for article (PubMed ID: 23110309)
81. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells.
Lin K; Rockliffe N; Johnson GG; Sherrington PD; Pettitt AR
Oncogene; 2008 Apr; 27(17):2445-55. PubMed ID: 17982489
[TBL] [Abstract][Full Text] [Related]
82. Exposure of B cell chronic lymphocytic leukemia (B-CLL) cells to nutlin-3 induces a characteristic gene expression profile, which correlates with nutlin-3-mediated cytotoxicity.
Zauli G; di Iasio MG; Secchiero P; Dal Bo M; Marconi D; Bomben R; Del Poeta G; Gattei V
Curr Cancer Drug Targets; 2009 Jun; 9(4):510-8. PubMed ID: 19519319
[TBL] [Abstract][Full Text] [Related]
83. A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis.
Bacalini MG; Tavolaro S; Peragine N; Marinelli M; Santangelo S; Del Giudice I; Mauro FR; Di Maio V; Ricciardi MR; Caiafa P; Chiaretti S; Foà R; Guarini A; Reale A
Exp Hematol; 2012 Mar; 40(3):197-206.e1. PubMed ID: 22120020
[TBL] [Abstract][Full Text] [Related]
84. TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia.
Malcikova J; Pavlova S; Kozubik KS; Pospisilova S
Hum Mutat; 2014 Jun; 35(6):663-71. PubMed ID: 24415659
[TBL] [Abstract][Full Text] [Related]
85. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.
Stilgenbauer S; Eichhorst B; Schetelig J; Hillmen P; Seymour JF; Coutre S; Jurczak W; Mulligan SP; Schuh A; Assouline S; Wendtner CM; Roberts AW; Davids MS; Bloehdorn J; Munir T; Böttcher S; Zhou L; Salem AH; Desai M; Chyla B; Arzt J; Kim SY; Verdugo M; Gordon G; Hallek M; Wierda WG
J Clin Oncol; 2018 Jul; 36(19):1973-1980. PubMed ID: 29715056
[TBL] [Abstract][Full Text] [Related]
86. A new genetic abnormality leading to TP53 gene deletion in chronic lymphocytic leukaemia.
López C; Baumann T; Costa D; López-Guerra M; Navarro A; Gómez C; Arias A; Muñoz C; Rozman M; Villamor N; Colomer D; Montserrat E; Campo E; Carrió A
Br J Haematol; 2012 Mar; 156(5):612-8. PubMed ID: 22150335
[TBL] [Abstract][Full Text] [Related]
87. 17p Deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis.
Turgut B; Vural O; Pala FS; Pamuk GE; Tabakcioğlu K; Demir M; Ongören S; Soysal T; Algüneş C
Leuk Lymphoma; 2007 Feb; 48(2):311-20. PubMed ID: 17325891
[TBL] [Abstract][Full Text] [Related]
88. p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.
Schlette EJ; Admirand J; Wierda W; Abruzzo L; Lin KI; O'Brien S; Lerner S; Keating MJ; Tam C
Leuk Lymphoma; 2009 Oct; 50(10):1597-605. PubMed ID: 19863337
[TBL] [Abstract][Full Text] [Related]
89. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
[TBL] [Abstract][Full Text] [Related]
90. [Some genomic aberrations in B-cell chronic lymphocytic leukemia and their clinical relevance. Part II. Trisomy 12 in B-cell chronic lymphocytic leukemia detected by fluorescence in situ hybridization].
Wasik-Szczepanek E; Rupniewska ZM; Koczkodaj D; Bojarska A
Pol Arch Med Wewn; 2003 Dec; 110(6):1431-8. PubMed ID: 15052938
[TBL] [Abstract][Full Text] [Related]
91. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.
Pettitt AR; Jackson R; Carruthers S; Dodd J; Dodd S; Oates M; Johnson GG; Schuh A; Matutes E; Dearden CE; Catovsky D; Radford JA; Bloor A; Follows GA; Devereux S; Kruger A; Blundell J; Agrawal S; Allsup D; Proctor S; Heartin E; Oscier D; Hamblin TJ; Rawstron A; Hillmen P
J Clin Oncol; 2012 May; 30(14):1647-55. PubMed ID: 22493413
[TBL] [Abstract][Full Text] [Related]
92. Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
Cramer P; Langerbeins P; Eichhorst B; Hallek M
Eur J Haematol; 2016 Jan; 96(1):9-18. PubMed ID: 26332019
[TBL] [Abstract][Full Text] [Related]
93. Jumping translocations, a novel finding in chronic lymphocytic leukaemia.
Miller CR; Stephens D; Ruppert AS; Racke F; McFaddin A; Breidenbach H; Lin HJ; Waller K; Bannerman T; Jones JA; Woyach JA; Andritsos LA; Maddocks K; Zhao W; Lozanski G; Flynn JM; Grever M; Byrd JC; Heerema NA
Br J Haematol; 2015 Jul; 170(2):200-7. PubMed ID: 25891862
[TBL] [Abstract][Full Text] [Related]
94. Frequency of TP53 Mutation in B-Cell Chronic Lymphocytic Leukaemia and its Association with Lymphocyte Doubling Time.
Ali SM; Irfan SM; Raza N
J Coll Physicians Surg Pak; 2023 Nov; 33(11):1249-1253. PubMed ID: 37926876
[TBL] [Abstract][Full Text] [Related]
95. The clinical implications of gene mutations in chronic lymphocytic leukaemia.
Rossi D; Gaidano G
Br J Cancer; 2016 Apr; 114(8):849-54. PubMed ID: 27031852
[TBL] [Abstract][Full Text] [Related]
96. Distinct p53 phosphorylation patterns in chronic lymphocytic leukemia patients are reflected in the activation of circumjacent pathways upon DNA damage.
Mancikova V; Pesova M; Pavlova S; Helma R; Zavacka K; Hejret V; Taus P; Hynst J; Plevova K; Malcikova J; Pospisilova S
Mol Oncol; 2023 Jan; 17(1):82-97. PubMed ID: 36334078
[TBL] [Abstract][Full Text] [Related]
97. Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.
Visentin A; Mauro FR; Cibien F; Vitale C; Reda G; Fresa A; Ciolli S; Pietrasanta D; Marchetti M; Murru R; Gentile M; Rigolin GM; Quaglia FM; Scarfò L; Sportoletti P; Pravato S; Piazza F; Coscia M; Laurenti L; Molica S; Foà R; Cuneo A; Trentin L
Am J Hematol; 2022 Mar; 97(3):E95-E99. PubMed ID: 34904743
[No Abstract] [Full Text] [Related]
98. Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation.
László T; Kotmayer L; Fésüs V; Hegyi L; Gróf S; Nagy Á; Kajtár B; Balogh A; Weisinger J; Masszi T; Nagy Z; Farkas P; Demeter J; Istenes I; Szász R; Gergely L; Sulák A; Borbényi Z; Lévai D; Schneider T; Pettendi P; Bodai E; Szerafin L; Rejtő L; Bátai Á; Dömötör MÁ; Sánta H; Plander M; Szendrei T; Hamed A; Lázár Z; Pauker Z; Radványi G; Kiss A; Körösmezey G; Jakucs J; Dombi PJ; Simon Z; Klucsik Z; Gurzó M; Tiboly M; Vidra T; Ilonczai P; Bors A; Andrikovics H; Egyed M; Székely T; Masszi A; Alpár D; Matolcsy A; Bödör C
J Pathol Clin Res; 2024 Jan; 10(1):e351. PubMed ID: 37987115
[TBL] [Abstract][Full Text] [Related]
99. TP53 mutations in CLL: does frequency matter?
Al-Sawaf O; Fischer K
Blood; 2021 Dec; 138(25):2600-2601. PubMed ID: 34940820
[No Abstract] [Full Text] [Related]
100. Presence of mutant p53 increases stem cell frequency and is associated with reduced binding to classic TP53 binding sites in cell lines and primary AMLs.
Gerritsen M; Hilgendorf S; Yi G; Wierenga ATJ; Schuringa JJ; Martens JHA; Vellenga E
Exp Hematol; 2022 Jun; 110():39-46. PubMed ID: 35315319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
